Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6020388 | Journal of Neuroimmunology | 2014 | 7 Pages |
Abstract
Positive anti-JC virus antibody status, prior use of immunosuppressants, and increasing duration of natalizumab treatment have been proposed as risk factors for progressive multifocal leukoencephalopathy in multiple sclerosis patients, but while they may help to identify the most appropriate patients for natalizumab, their use have some limitations. Therefore, a large body of studies is ongoing to identify alternative, reliable immunological markers capable to improve the safety and efficacy of therapy, and to guide tailored clinical decisions.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Federico Serana, Marco Chiarini, Alessandra Sottini, Diego Bertoli, Viviana Giustini, Marion Vaglio Tessitore, Luigi Caimi, Ruggero Capra, Luisa Imberti,